Biomarkers in pulmonary embolism

Area of Science:

• Cardiology
• Pulmonary Medicine
• Biomarker Research

Background:

• Pulmonary embolism (PE) diagnosis and risk stratification remain challenging.
• The role of thrombolytic therapy in normotensive PE patients is debated.
• Identifying high-risk PE subgroups is crucial for guiding treatment decisions.

Purpose of the Study:

• To assess the utility of cardiac biomarkers (Troponin I/T, BNP) in identifying high-risk normotensive PE patients.
• To evaluate whether elevated biomarkers justify expanded use of thrombolytic therapy.
• To determine the predictive value of biomarkers for adverse outcomes in PE.

Main Methods:

• Review of studies on cardiac biomarker levels in PE patients.
• Analysis of the prevalence of elevated cardiac biomarkers (Troponin I/T, BNP).
• Evaluation of positive and negative predictive values of biomarkers for in-hospital mortality and uneventful outcomes.

Main Results:

• Prevalence of elevated cardiac biomarkers in PE patients ranged from 16% to 84%.
• Positive predictive values for in-hospital mortality varied significantly (6% to 44%).
• Negative predictive values for uneventful outcomes consistently exceeded 93%.

Conclusions:

• While elevated cardiac biomarkers correlate with in-hospital mortality in PE, their positive predictive value is insufficient for widespread thrombolytic therapy indication.
• Further research is required to determine if combining biomarkers with echocardiography can improve risk stratification in PE.
• Current evidence does not support extending thrombolytic therapy to all PE patients with elevated biomarkers.